Defendant

Biocon Ltd.

1 case as defendant.

Cases
1
Active
0
1 closed
Filed
—
Top venue
D N J
1 case

Company profile

Biocon Limited (NSE: BIOCON; BSE: 532523) is an Indian biopharmaceutical company headquartered in Bengaluru, Karnataka, with US headquarters in Bridgewater, New Jersey. Founded in 1978 by Kiran Mazumdar-Shaw, it has been publicly listed since 2004 and has no holding company. FY2025 group revenue was roughly ₹16,470 crore, and the group reported about 16,500 employees (Wikipedia; company filings).

Products / operations. Biocon operates three main segments. Biosimilars, run through subsidiary Biocon Biologics, has commercialized around ten biosimilars across diabetology, oncology, immunology and ophthalmology (e.g., insulin glargine, trastuzumab, pegfilgrastim, ustekinumab, aflibercept) for the US, Europe, Japan and emerging markets. Generics covers active pharmaceutical ingredients and generic formulations — immunosuppressants, cardiovascular, anti-diabetics and peptide/GLP-1 products — including a US oral solid dosage site in Cranbury, New Jersey. Research services are delivered by separately listed subsidiary Syngene International, a contract research, development and manufacturing organization (CRDMO) spanning small and large molecules. Biocon also has early-stage novel biologics programs.

Litigation posture. The tracked data show Biocon as a defendant in one case and a plaintiff in none, consistent with an operating company being sued rather than a patent assertion entity. The single tracked matter, Celgene Corp. v. Biocon Pharma Ltd. et al., was filed in the District of New Jersey in May 2021 (No. 2:21-cv-11261) as a Hatch-Waxman ANDA patent-infringement action concerning Celgene's Revlimid/Thalomid (lenalidomide/thalidomide) patents; Biocon entities answered and counterclaimed. Venue was D.N.J. — the District of New Jersey, not a plaintiff-friendly Texas venue.

Context. Celgene is a wholly-owned subsidiary of Bristol Myers Squibb, which acquired it in 2019. Biocon subsequently disclosed a confidential settlement with Celgene relating to the Revlimid patents. No other patent suits involving Biocon appear in the tracked data.